Biospecimen Collection in Assessing the Effect of Trametinib With or Without Uprosertib on Biomarkers in Patients With Persistent or Recurrent Endometrial Cancer Enrolled on Trial GOG02290

Recurrent Endometrial Carcinoma Clinical Trial

Official title:
A Translational Companion Protocol to GOG229O: A Randomized Phase II Study With a Safety Lead-In to Assess the Antitumor Efficacy of the MEK Inhibitor Trametinib Alone or in Combination With GSK2141795, an AKT Inhibitor, in Patients With Recurrent or Persistent Endometrial Cancer

Status Completed

Clinical Trial Summary

This trial assesses blood and tumor samples for the effect of trametinib with or without uprosertib on biomarkers in patients enrolled on trial GOG02290 with endometrial cancer that is persistent or has come back. Biomarkers found in the blood and tissue may be related to the reaction or response to the study drugs.

Clinical Trial Description

PRIMARY OBJECTIVES:

I. To explore the impact of trametinib alone or in combination with uprosertib (GSK2141795) on RAF-MEK-ERK and PI3K pathway signaling.

SECONDARY OBJECTIVES:

I. To examine associations with early changes in functional proteomic biomarkers in tumor biopsies before and after treatment and tumor response in two subgroups of patients with recurrent or persistent endometrial cancer who are treated with trametinib alone or in combination with GSK2141795.

II. To examine levels of circulating tumor cells in blood samples before and after treatment and correlate with tumor response in two subgroups of patients with recurrent or persistent endometrial cancer who are treated with trametinib alone or in combination with GSK2141795.

III. To examine the bRaf/cRaf dimer or Raf/KSR/Mek1 dimers in paraffin sections from these patients before treatment by proximity ligation assay (PLA) assays.

IV. To quantify exosomes from these patients before and after treatment by enzyme-linked immunosorbent assay (ELISA) assay with CD63 antibody and explore bRaf/cRaf dimer or Raf/KSR/Mek1 dimers in exosomes from these patients before and after treatment by PLA assays.

OUTLINE:

Patients undergo collection of blood at screening, between days 3 and 5, 28, and 56. Patients also undergo collection of tumor biopsy at screening and day 28. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02093546
Study type	Observational
Source	M.D. Anderson Cancer Center
Contact
Status	Completed
Phase
Start date	August 13, 2004
Completion date	January 15, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03968406` - Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers	Phase 1
Active, not recruiting	`NCT03508570` - Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis	Phase 1
Completed	`NCT00723255` - Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer	Phase 2
Completed	`NCT00025467` - Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer	Phase 2
Active, not recruiting	`NCT03120624` - VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer	Phase 1
Recruiting	`NCT05691504` - Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers	Phase 1
Active, not recruiting	`NCT04781088` - Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Phase 2
Completed	`NCT01764789` - Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer	N/A
Recruiting	`NCT04469764` - Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer	Phase 2
Terminated	`NCT03924245` - Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers	Phase 1
Completed	`NCT00462826` - VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer	Phase 2
Completed	`NCT00096447` - Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer	Phase 2
Completed	`NCT00028535` - Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors	Phase 1
Completed	`NCT01652794` - Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer	Phase 1
Completed	`NCT01079832` - Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies	Phase 2
Completed	`NCT00095979` - Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer	Phase 2
Completed	`NCT00072176` - Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer	Phase 2
Withdrawn	`NCT01943058` - Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer	Phase 2
Completed	`NCT00301964` - Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancer	Phase 2
Completed	`NCT01155258` - Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors	Phase 1